https://www.selleckchem.com/pr....oducts/trastuzumab-e
131 (20.4%) and 512 (79.6%) had no or had co-morbidities, respectively. Smoking (10 py) was significantly associated with co-morbidities (p = 0.002). However, smoking and co-morbidities, neither alone nor in combination, were correlated with failure in reaching target doses of radichemo)therapy (p 0.05). Applying (verified) Carlson-Comorbidity-Index (CCI) did not change the results. Conclusions As expected, smoking is significantly associated with co-morbidities. Dose-reduction of radichemo)therapy is a